ARS Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ARS Pharmaceuticals (SPRY).

Price Target Range — 8 Quarters

Analyst Consensus — 5 Analysts

1S.Buy

4Buy

Consensus RatingOutperform# Analysts5Avg. Consensus PT$28Upside to Avg. PT+651.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	Leerink Partners	Roanna Ruiz	PT Cut	Outperform	$24→$18
Jun 25, 2026	Leerink Partners	Roanna Ruiz	PT Cut	Outperform	$25→$24
May 28, 2026	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$12→$30
Sep 4, 2025	Roth Capital	Jason Wittes	Initiate	Buy	$40
Mar 7, 2025	Scotiabank	Louise Chen	Initiate	Sector Outperform	$30
Jan 14, 2025	Raymond James	Ryan Deschner	PT Raise	Strong Buy	$26→$28
Jan 13, 2025	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$26→$27
Oct 8, 2024	Cantor Fitzgerald	Josh Schimmer	Maintained	Overweight	$30
Sep 20, 2024	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$21→$25
Sep 16, 2024	Cantor Fitzgerald	Josh Schimmer	Maintained	Overweight	$30
Sep 9, 2024	Cantor Fitzgerald	Josh Schimmer	Maintained	Overweight	$30
Aug 20, 2024	Cantor Fitzgerald	Josh Schimmer	Initiate	Overweight	$30
Aug 13, 2024	Raymond James	Ryan Deschner	Upgrade	Outperform→Strong Buy	$18→$22
Jul 25, 2024	Raymond James	Ryan Deschner	Initiate	Outperform	$18
Mar 11, 2024	Wedbush	Andreas Argyrides	Maintained	Outperform	$19
Mar 5, 2024	Leerink Partners	Roanna Ruiz	Upgrade	Market Perform→Outperform	$6→$18
Nov 13, 2023	Wedbush	Andreas Argyrides	PT Raise	Outperform	$5→$13

Analyst Ratings News

Can ARS Pharma's New CEO Unlock Neffy's Potential?

ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.

Vandana Singh

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for Neffy despite coverage setbacks.

Vandana Singh

PRO
Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24

Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $25 to $24.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30

Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.

Benzinga Newsdesk

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.

Avi Kapoor

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying potential competition.

Vandana Singh

ARS Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

ARS Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Can ARS Pharma's New CEO Unlock Neffy's Potential?

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

PRO
Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24

PRO
Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

People Also Watch

People Also Watch

ARS Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

ARS Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Can ARS Pharma's New CEO Unlock Neffy's Potential?

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

PROLeerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24

PROCantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24

PRO
Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30